Life Off Treatment
446 articles
FDA Approves Tumor Treating Fields For Locally Advanced Disease
Dr. Vincent Picozzi explains how the recently approved tumor treating fields device is changing the game for pancreatic cancer patients.
KRYSTAL-1 Trial Shows Promising Activity in Pancreas and Other GI Cancers
Dr. Tanios Bekaii-Saab reports promising results of the KRYSTAL-1 trial, which targets a KRAS mutation common to pancreatic cancer.
BRCA’s Role in Pancreatic Cancer Investigated
The relationship between BRCA and pancreatic cancer, and how that affects treatment, is the focus of clinical trials looking at PARP inhibitors.
Large Clinical Trial For Cachexia Treatment
Lead investigator Dr. Jeffrey Crawford reports on the positive results from a cachexia clinical trial of a new immunotherapy drug to treat the condition.
Potential Therapy Takes a Two-Prong Attack on Pancreatic Cancer
With a focus on targeting cell metabolism, Dr. Anup Kasi leads a clinical trial of a new agent in combination with gemcitabine.
Harnessing the Power of Radionuclide Therapy
Julie Sutcliffe is working with targeted radionuclide therapy to go after pancreatic cancer cells that have spread beyond the pancreas.
Combination Delivers a Dual Punch to Pancreatic Cell Growth
Dr. Conan Kinsey outlines a clinical trial that has moved quickly from the lab to phase I, with a dual approach to delivering pancreatic cancer treatment.
The Latest Research: The 2026 AACR Conference on Pancreatic Cancer
At the 2026 AACR Pancreatic Cancer conference, researchers reported on daraxonrasib and other KRAS targeting drugs.
PanCAN 2021 Annual Scientific Summit
Pancreatic Cancer Action Network (PanCAN) held its annual scientific summit for an overview of the latest research projects they are funding.
Comparing Two Types of Radiotherapy for Pancreatic Tumors that Cannot Be Surgically Removed
Researchers are comparing standard radiotherapy treatment with a newer type of radiation that uses heavy ions, for nonsurgical pancreatic cancer patients.
Pancreatic Cancer Research Highlights from ASCO GI 2025
Read about the pancreatic cancer research highlights from the ASCO GI 2025 conference, where treatments and quality-of-life were discussed.
The Future’s So Bright
Meet this year’s group of bright young scientists, who are setting the pace for pancreatic cancer research.
Most Cancer Mutations Are Random DNA Mistakes
In a large study, Dr. Bert Vogelstein of Johns Hopkins found that a majority of cancers, including pancreatic cancer, are caused by random mutations of DNA.
An Expanded Access Trial for Cancer Patients with Specific Mutations
An investigational drug is being used in an expanded access trial for advanced pancreatic and other cancer patients with specific genetic changes.
Slowing the Growth of One Type of Advanced Neuroendocrine Tumor
Dr. Kelsey Klute explains the advantages of the radiopharmaceutical lutetium Lu 177 dotatate treatment for certain neuroendocrine tumors.